Tremeau Completes $5.2M Equity Raise to Fund Non-Opioid Pain Treatments for Rare Diseases
CAMBRIDGE, Mass., Feb. 15, 2018 /PRNewswire/ -- Tremeau Pharmaceuticals, a new pharmaceutical company focused on providing non-opioid pain treatments for rare diseases, announced today that it closed its first equity round, having raised $5.2 million from investors. The funding will be used to advance Tremeau's pipeline of non-opioid pain treatment candidates.
"We are excited to close our first equity round. The feedback from the patient, medical, and investor communities regarding our strategy of providing non-opioid pain treatments for rare diseases, like hemophilic arthropathy, has been very positive," said Bradford C. Sippy, Chief Executive Officer of Tremeau. "We look forward to progressing our non-opioid pain candidates into the clinic."
About Hemophilic Arthropathy
Nonsteroidal anti-inflammatory drugs (NSAIDs), including rofecoxib, cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. NSAIDs, including rofecoxib, are contraindicated in the setting of coronary artery bypass graft (CABG). NSAIDs, including rofecoxib, cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.
Tremeau plans to develop and commercialize rofecoxib for the orphan indication of the treatment of hemophilic arthropathy and subsequent niche patient segments with no approved treatments and where it could have a strong benefit to risk ratio versus other therapies.
About FDA Orphan Drug Designation Program
About Tremeau Pharmaceuticals, Inc.
For additional information about Tremeau, please visit www.tremeaurx.com.
2. Srivastava et al., Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47
3. Witkop M, Lambing A, Divine G, Kachalsky E, Rushlow D, Dinnen J. A national study of pain in the bleeding disorders community: a description of haemophilia pain. Haemophilia 2012; 18: e115-19.
4. US Food and Drug Administration. VIOXX (Rofecoxib) U.S. Prescribing Information 5/9/2016, (accessed 9/27/2017)
5. US Food and Drug Administration. Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ (accessed 9/27/2017)
View original content with multimedia:http://www.prnewswire.com/news-releases/tremeau-completes-52-million-equity-raise-to-fund-non-opioid-pain-treatments-for-rare-diseases-300599188.html
SOURCE Tremeau Pharmaceuticals